TLDR
- AstraZeneca will invest $2 billion in Summit Therapeutics through a purchase of convertible preferred stock.
- Summit Therapeutics (SMMT) stock jumped about 15% in after-hours trading Monday on the news.
- The two companies will run clinical trials combining Summit’s ivonescimab with AstraZeneca’s sonesitatug vedotin.
- Goldman Sachs reiterated a Buy rating on Summit stock with a $41 price target.
- The FDA is set to decide by Nov. 14 whether to approve ivonescimab for a form of lung cancer.
Summit Therapeutics (SMMT) stock jumped about 15% in after-hours trading Monday. The move came after AstraZeneca (AZN) announced a $2 billion investment in the cancer drug developer.
Summit Therapeutics Inc., SMMT
The stock closed regular trading at $15.48, down close to 1% on the day. It had fallen about 10% over the past week before the deal news broke.
AstraZeneca will buy convertible preferred stock at a price equal to $18.36 per Summit common share equivalent. That works out to a 10% premium to Summit’s volume-weighted average price over the prior five trading days.
The deal is expected to close by the end of this week. It gives AstraZeneca exposure to a promising cancer treatment without buying Summit outright.
The Clinical Collaboration
The two companies will work together on trials combining Summit’s flagship drug ivonescimab with AstraZeneca’s experimental treatment sonesitatug vedotin. The initial focus is gastrointestinal cancers.
Both companies will split the cost of the trials. Each side keeps commercial rights to its own compound.
Ivonescimab was first developed by China’s Akeso. Summit licensed the drug in a deal worth up to $5 billion and holds rights to sell it in the U.S. and Europe.
The drug is already approved in China. Investors will be watching how it performs in other markets going forward.
What’s Next for the FDA Decision
The FDA is set to decide by Nov. 14 whether to approve ivonescimab, paired with chemotherapy, for a form of lung cancer. That call could be a major swing factor for the stock.
Summit’s Phase 3 HARMONi-3 study is also underway. It is testing ivonescimab with chemotherapy in frontline non-small cell lung cancer.
Final progression-free survival data and interim overall survival numbers from the squamous cohort are expected by year-end. Traders will be watching those results closely.
On Tuesday, Goldman Sachs reiterated its Buy rating on Summit stock. The bank kept its price target at $41.
Goldman analyst Satoru Ogawa said the non-exclusive partnership gives Summit access to AstraZeneca’s antibody drug conjugate pipeline. That could help the company find better combinations for individual cancers.
Summit already has partnerships with Revolution Medicines, GSK, and Arcus Biosciences. Those deals cover other experimental cancer treatments in its pipeline.
AstraZeneca’s U.S.-listed stock rose about 1% in after-hours trading following the announcement. The new investment adds cash to Summit’s balance sheet, which stood at $690.7 million at the end of the last quarter.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
